MJ Biopharm Pvt. Ltd.
MJ Biopharm is a trusted name in biopharmaceutical manufacturing with a heritage of more than 25 years. While our core strength lies in end-to-end insulin production — from E. coli fermentation to finished formulations — our capabilities extend beyond diabetes care. We also specialize in Dry Powder Injectables (DPI) as well as sterile tablets and capsules, ensuring a comprehensive portfolio of critical care medicines.
Today, we are one of the largest suppliers of insulin to the Government of India and a trusted partner in over 50 countries worldwide. Our mission is to deliver high-quality, affordable medicines on time, improving access to life-saving treatments across therapeutic areas.
What We Do
Diabetes Care
Complete insulin portfolio (vials, cartridges, disposable pen devices) supported by a strong biosimilar pipeline.
Dry Powder Injectables (DPI)
Advanced DPI manufacturing for respiratory and critical care treatments.
Sterile Tablets & Capsules
High-quality oral dosage forms to complement our injectable portfolio.
Global Supply
Trusted by governments and healthcare providers in India and across 50+ countries.
Key Strengths
World-Class Manufacturing
WHO-GMP certified facilities with PIC/S approval (South Africa) and global regulatory readiness.
Diversified Capabilities
Insulins, DPI, sterile tablets, and capsules.
100L Pilot Plant
Dedicated pilot facility to support R&D, process optimization, and clinical batch manufacturing.
R&D Innovation
Strong pipeline of biosimilars, insulins, and GLP-1 products.
Global Reach
Supplying millions of patients in India and across the world.
Proven Reliability
Decades of experience in critical care and life-saving formulations.
Our Facilities
Service Name
Describe the service and how customers or clients can benefit from it.
Service Name
Describe the service and how customers or clients can benefit from it.
Service Name
Describe the service and how customers or clients can benefit from it.
Service Name
Describe the service and how customers or clients can benefit from it.
Service Name
Describe the service and how customers or clients can benefit from it.
Research & Development
End-to-end product development from preclinical to regulatory approval.
Pipeline includes biosimilar insulins (Glargine, Aspart, Lispro, Degludec) and GLP-1 analogues (Liraglutide, Semaglutide).
Specialized in formulation development, technology transfer, dossier preparation, and lifecycle management.
100L Pilot Plant supports seamless scale-up and clinical trial readiness.
Partnerships advancing extended-release GLP-1 formulations and respiratory therapies.
Future Outlook
MJ Biopharm will continue to expand its capacity in insulin and biosimilars while strengthening its position in Dry Powder Injectables and sterile oral formulations. With innovation at the core and compliance at the highest standards, we aim to deliver sustainable, affordable healthcare solutions to patients across the globe.